Supplementary Material

Optineurin suppression activates the mediators involved in the terminal effector pathways of human labour and delivery

Ratana Lim\textsuperscript{A,B}, Gillian Barker\textsuperscript{A,B} and Martha Lappas\textsuperscript{A,B}

\textsuperscript{A}Obstetrics, Nutrition and Endocrinology Group, Department of Obstetrics and Gynaecology, The University of Melbourne, Vic. 3084, Australia.

\textsuperscript{B}Mercy Perinatal Research Centre, Mercy Hospital for Women, 4th Floor, 163 Studley Rd, Heidelberg, Vic. 3084, Australia.

\textsuperscript{C}Corresponding author. Email: mlappas@unimelb.edu.au
**Fig. S1.** Efficacy of siOPTN knockdown. Human primary myometrial cells were transfected with 100 nM siOPTN or 100 nM siCONT for 48 h (n=5 patients). (A) Optineurin gene expression was analysed by qRT-PCR. Gene expression was normalised to 18S rRNA expression and the fold change was calculated relative to the siCONT transfected cells. Data is displayed as mean ± SEM. *P<0.05 vs. siCONT (one-sample t-test). (B) Optineurin protein expression was analysed by Western blot. Protein expression was normalised to β-actin and the fold change was calculated to the siCONT transfected cells. Data is displayed as mean ± SEM. *P<0.05 vs. siCONT (Student’s t-test). Western blot of one patient sample is shown. (C) Cell viability was assessed using a MTT assay and the fold change was calculated relative to the siCONT transfected cells. Data is displayed as mean ± SEM. *P<0.05 vs. siCONT (one-sample t-test).